Annual report
7745.TEDINET S100W7MR
Period2024-04-01 → 2025-03-31
Filed2025-06-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 155
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥67.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥62.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥59.0bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥51.7bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥48.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥8.8bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥8.0bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥9.0bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥8.2bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥7.6bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.6bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.6bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥9.1bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥8.0bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥6.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.3bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.5bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.6bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.3bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥6.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥5.3bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥69.0bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥72.0bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥69.4bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥59.2bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥54.1bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥26.2bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥34.2bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥42.8bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥37.8bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥32.6bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥27.0bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥23.4bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥13.3bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥14.6bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥13.3bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.3bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.0bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥12.1bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥6.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥7.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥4.1bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.8bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥5.2bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.4bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.2bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥5.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥452m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥741m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥257m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥235.63 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥192.91 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥201.33 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥172.92 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥161.87 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥235.41 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥192.73 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥201.14 | 2022-04-01 → 2023-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥172.66 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥161.5 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,560.29 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,370.71 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,183.98 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,167.95 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,007.01 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 61.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.3% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.8% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.8% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.4% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 16.1% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 15.1% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 19.5% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 15.9% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 17.6% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 2,438 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 2,471 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 2,495 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 2,591 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 2,544 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥3.2bn | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥2.5bn | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥1.5bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥35.0bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥33.1bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥2.6bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥2.1bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥2.4bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.6bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥739m | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.6bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.7bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.6bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥1.6bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥2.3bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥1.3bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥415m | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥2.0bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥2.1bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥38.2bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥39.3bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥36.7bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥39.6bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥38.9bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥12.5bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥14.6bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥25.7bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥24.8bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥24.4bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥18.6bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥17.2bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.2bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.3bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥83.15 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.72 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.15 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥95.62 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥101.03 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥83.07 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥46.67 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥15.13 | 2022-04-01 → 2023-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥95.48 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥100.8 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥40 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥35 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥35 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥937.8 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥900.94 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥889.74 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥897.51 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥833.78 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 67.2% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.0% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.6% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.9% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.2% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 9.1% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.2% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.9% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.1% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.7% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 27,845,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 27,845,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 27,845,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 22,601,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 22,579,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 743 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 732 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 178
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥85m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥64m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥28.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥28.4bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | −¥13.9bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥2.1bn |
| America Measuring Instrumentsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥21m |
| America Measuring Instrumentsreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥65m |
| America Measuring Instrumentsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥6.1bn |
| America Measuring Instrumentsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥5.7bn |
| America Measuring Instrumentsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥389m |
| America Measuring Instrumentsreportable segment | segment assets | at 2025-03-31 | ¥3.7bn |
| America Measuring Instrumentsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥69m |
| America Medical And Health Systemreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥44m |
| America Medical And Health Systemreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥68m |
| America Medical And Health Systemreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥10.0bn |
| America Medical And Health Systemreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥10.0bn |
| America Medical And Health Systemreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥2m |
| America Medical And Health Systemreportable segment | segment assets | at 2025-03-31 | ¥5.1bn |
| America Medical And Health Systemreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥472m |
| Asia And Oceania Measuring Instrumentsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥136m |
| Asia And Oceania Measuring Instrumentsreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥159m |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥9.1bn |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥5.6bn |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥3.5bn |
| Asia And Oceania Measuring Instrumentsreportable segment | segment assets | at 2025-03-31 | ¥7.5bn |
| Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥588m |
| Asia And Oceania Medical And Health Systemreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥47m |
| Asia And Oceania Medical And Health Systemreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥232m |
| Asia And Oceania Medical And Health Systemreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥8.7bn |
| Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥493m |
| Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥8.2bn |
| Asia And Oceania Medical And Health Systemreportable segment | segment assets | at 2025-03-31 | ¥3.8bn |
| Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥224m |
| Europe Measuring Instrumentsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥1m |
| Europe Measuring Instrumentsreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥2m |
| Europe Measuring Instrumentsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥650m |
| Europe Measuring Instrumentsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥649m |
| Europe Measuring Instrumentsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥0 |
| Europe Measuring Instrumentsreportable segment | segment assets | at 2025-03-31 | ¥364m |
| Europe Measuring Instrumentsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥28m |
| Europe Medical And Health Systemreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥44m |
| Europe Medical And Health Systemreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥95m |
| Europe Medical And Health Systemreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥8.8bn |
| Europe Medical And Health Systemreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥8.8bn |
| Europe Medical And Health Systemreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥0 |
| Europe Medical And Health Systemreportable segment | segment assets | at 2025-03-31 | ¥8.3bn |
| Europe Medical And Health Systemreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥193m |
| Japan Measuring Instrumentsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥809m |
| Japan Measuring Instrumentsreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥642m |
| Japan Measuring Instrumentsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥22.2bn |
| Japan Measuring Instrumentsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥18.7bn |
| Japan Measuring Instrumentsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥3.5bn |
| Japan Measuring Instrumentsreportable segment | segment assets | at 2025-03-31 | ¥32.2bn |
| Japan Measuring Instrumentsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥2.1bn |
| Japan Medical And Health Systemreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥351m |
| Japan Medical And Health Systemreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥219m |
| Japan Medical And Health Systemreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥17.7bn |
| Japan Medical And Health Systemreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥4.8bn |
| Japan Medical And Health Systemreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥12.9bn |
| Japan Medical And Health Systemreportable segment | segment assets | at 2025-03-31 | ¥7.8bn |
| Japan Medical And Health Systemreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥3.2bn |
| Japan Semiconductor Related Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥844m |
| Japan Semiconductor Related Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥231m |
| Japan Semiconductor Related Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥12.3bn |
| Japan Semiconductor Related Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥12.3bn |
| Japan Semiconductor Related Businessreportable segment | segment assets | at 2025-03-31 | ¥14.2bn |
| Japan Semiconductor Related Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥4.1bn |
| Measurement Weighing Instruments Businessesreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥969m |
| Measurement Weighing Instruments Businessesreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥869m |
| Measurement Weighing Instruments Businessesreportable segment | employees | at 2025-03-31 | 1120 pure |
| Measurement Weighing Instruments Businessesreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥38.0bn |
| Measurement Weighing Instruments Businessesreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥30.7bn |
| Measurement Weighing Instruments Businessesreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥7.3bn |
| Measurement Weighing Instruments Businessesreportable segment | segment assets | at 2025-03-31 | ¥43.8bn |
| Measurement Weighing Instruments Businessesreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥2.7bn |
| Medical Healthcare Instruments Businessesreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥488m |
| Medical Healthcare Instruments Businessesreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥616m |
| Medical Healthcare Instruments Businessesreportable segment | employees | at 2025-03-31 | 1129 pure |
| Medical Healthcare Instruments Businessesreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥45.2bn |
| Medical Healthcare Instruments Businessesreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥24.1bn |
| Medical Healthcare Instruments Businessesreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥21.1bn |
| Medical Healthcare Instruments Businessesreportable segment | segment assets | at 2025-03-31 | ¥24.9bn |
| Medical Healthcare Instruments Businessesreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥4.1bn |
| Semiconductor Related Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥844m |
| Semiconductor Related Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥231m |
| Semiconductor Related Businessreportable segment | employees | at 2025-03-31 | 137 pure |
| Semiconductor Related Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥12.3bn |
| Semiconductor Related Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥12.3bn |
| Semiconductor Related Businessreportable segment | segment assets | at 2025-03-31 | ¥14.2bn |
| Semiconductor Related Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥4.1bn |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥45m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥66m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥24.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥24.7bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | −¥10.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥1.8bn |
| America Measuring Instrumentsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥45m |
| America Measuring Instrumentsreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥59m |
| America Measuring Instrumentsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥4.8bn |
| America Measuring Instrumentsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥4.2bn |
| America Measuring Instrumentsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥595m |
| America Measuring Instrumentsreportable segment | segment assets | at 2024-03-31 | ¥4.1bn |
| America Measuring Instrumentsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥158m |
| America Medical And Health Systemreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥5m |
| America Medical And Health Systemreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥58m |
| America Medical And Health Systemreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥9.8bn |
| America Medical And Health Systemreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥9.8bn |
| America Medical And Health Systemreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥0 |
| America Medical And Health Systemreportable segment | segment assets | at 2024-03-31 | ¥5.2bn |
| America Medical And Health Systemreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥609m |
| Asia And Oceania Measuring Instrumentsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥144m |
| Asia And Oceania Measuring Instrumentsreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥146m |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥7.5bn |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥4.9bn |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥2.6bn |
| Asia And Oceania Measuring Instrumentsreportable segment | segment assets | at 2024-03-31 | ¥7.6bn |
| Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥260m |
| Asia And Oceania Medical And Health Systemreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥94m |
| Asia And Oceania Medical And Health Systemreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥225m |
| Asia And Oceania Medical And Health Systemreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥8.2bn |
| Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥377m |
| Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥7.8bn |
| Asia And Oceania Medical And Health Systemreportable segment | segment assets | at 2024-03-31 | ¥4.2bn |
| Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥335m |
| Europe Measuring Instrumentsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥2m |
| Europe Measuring Instrumentsreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥9m |
| Europe Measuring Instrumentsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥601m |
| Europe Measuring Instrumentsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥601m |
| Europe Measuring Instrumentsreportable segment | segment assets | at 2024-03-31 | ¥422m |
| Europe Measuring Instrumentsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥104m |
| Europe Medical And Health Systemreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥64m |
| Europe Medical And Health Systemreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥93m |
| Europe Medical And Health Systemreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥8.0bn |
| Europe Medical And Health Systemreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥8.0bn |
| Europe Medical And Health Systemreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥16m |
| Europe Medical And Health Systemreportable segment | segment assets | at 2024-03-31 | ¥7.5bn |
| Europe Medical And Health Systemreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥425m |
| Japan Measuring Instrumentsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥520m |
| Japan Measuring Instrumentsreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥714m |
| Japan Measuring Instrumentsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥20.9bn |
| Japan Measuring Instrumentsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥18.3bn |
| Japan Measuring Instrumentsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥2.6bn |
| Japan Measuring Instrumentsreportable segment | segment assets | at 2024-03-31 | ¥31.0bn |
| Japan Measuring Instrumentsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.4bn |
| Japan Medical And Health Systemreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥456m |
| Japan Medical And Health Systemreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥180m |
| Japan Medical And Health Systemreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥16.5bn |
| Japan Medical And Health Systemreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥5.4bn |
| Japan Medical And Health Systemreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥11.1bn |
| Japan Medical And Health Systemreportable segment | segment assets | at 2024-03-31 | ¥9.5bn |
| Japan Medical And Health Systemreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥2.9bn |
| Japan Semiconductor Related Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥1.0bn |
| Japan Semiconductor Related Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥194m |
| Japan Semiconductor Related Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥10.3bn |
| Japan Semiconductor Related Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥10.3bn |
| Japan Semiconductor Related Businessreportable segment | segment assets | at 2024-03-31 | ¥12.9bn |
| Japan Semiconductor Related Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥3.8bn |
| Measurement Weighing Instruments Businessesreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥712m |
| Measurement Weighing Instruments Businessesreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥929m |
| Measurement Weighing Instruments Businessesreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥33.8bn |
| Measurement Weighing Instruments Businessesreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥28.1bn |
| Measurement Weighing Instruments Businessesreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥5.8bn |
| Measurement Weighing Instruments Businessesreportable segment | segment assets | at 2024-03-31 | ¥43.2bn |
| Measurement Weighing Instruments Businessesreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.8bn |
| Medical Healthcare Instruments Businessesreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥621m |
| Medical Healthcare Instruments Businessesreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥556m |
| Medical Healthcare Instruments Businessesreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥42.5bn |
| Medical Healthcare Instruments Businessesreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥23.6bn |
| Medical Healthcare Instruments Businessesreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥18.9bn |
| Medical Healthcare Instruments Businessesreportable segment | segment assets | at 2024-03-31 | ¥26.3bn |
| Medical Healthcare Instruments Businessesreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥4.2bn |
| Semiconductor Related Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥1.0bn |
| Semiconductor Related Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥194m |
| Semiconductor Related Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥10.3bn |
| Semiconductor Related Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥10.3bn |
| Semiconductor Related Businessreportable segment | segment assets | at 2024-03-31 | ¥12.9bn |
| Semiconductor Related Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥3.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,939
| Item | Context | Value | Unit |
|---|---|---|---|
| Total assets (5-year summary) | CurrentYearInstant | 69005000000 | JPY |
| Net assets per share (5-year summary) | Prior4YearInstant | 1007.01 | |
| Net assets per share (5-year summary) | Prior3YearInstant | 1167.95 | |
| Net assets per share (5-year summary) | Prior2YearInstant | 1183.98 | |
| Net assets per share (5-year summary) | Prior1YearInstant | 1370.71 | |
| Net assets per share (5-year summary) | CurrentYearInstant | 1560.29 | |
| Basic earnings loss per share (5-year summary) | Prior4YearDuration | 161.87 | |
| Basic earnings loss per share (5-year summary) | Prior3YearDuration | 172.92 | |
| Basic earnings loss per share (5-year summary) | Prior2YearDuration | 201.33 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 192.91 | |
| Basic earnings loss per share (5-year summary) | CurrentYearDuration | 235.63 | |
| Diluted earnings per share (5-year summary) | Prior4YearDuration | 161.50 | |
| Diluted earnings per share (5-year summary) | Prior3YearDuration | 172.66 | |
| Diluted earnings per share (5-year summary) | Prior2YearDuration | 201.14 | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | 192.73 | |
| Diluted earnings per share (5-year summary) | CurrentYearDuration | 235.41 | |
| Equity to asset ratio (5-year summary) | Prior4YearInstant | 0.384 | |
| Equity to asset ratio (5-year summary) | Prior3YearInstant | 0.408 | |
| Equity to asset ratio (5-year summary) | Prior2YearInstant | 0.468 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.523 | |
| Equity to asset ratio (5-year summary) | CurrentYearInstant | 0.619 | |
| Rate of return on equity (5-year summary) | Prior4YearDuration | 0.176 | |
| Rate of return on equity (5-year summary) | Prior3YearDuration | 0.159 | |
| Rate of return on equity (5-year summary) | Prior2YearDuration | 0.195 | |
| Rate of return on equity (5-year summary) | Prior1YearDuration | 0.151 | |
| Rate of return on equity (5-year summary) | CurrentYearDuration | 0.161 | |
| Price earnings ratio (5-year summary) | Prior4YearDuration | 7.69 | |
| Price earnings ratio (5-year summary) | Prior3YearDuration | 5.60 | |
| Price earnings ratio (5-year summary) | Prior2YearDuration | 7.07 | |
| Price earnings ratio (5-year summary) | Prior1YearDuration | 15.03 | |
| Price earnings ratio (5-year summary) | CurrentYearDuration | 7.78 | |
| Net cash provided by used in operating activities (5-year summary) | Prior4YearDuration | 5194000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior3YearDuration | 1782000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior2YearDuration | 4096000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 7201000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYearDuration | 6578000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior4YearDuration | -2222000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior3YearDuration | -2395000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior2YearDuration | -1364000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -2007000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYearDuration | -2005000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior4YearDuration | -257000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior3YearDuration | -741000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior2YearDuration | 452000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | -5674000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYearDuration | -5440000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior4YearInstant | 12129000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior3YearInstant | 11012000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior2YearInstant | 14315000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 14016000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |